Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

26.53
+0.88003.43%
Post-market: 25.99-0.5400-2.04%19:30 EDT
Volume:1.62M
Turnover:43.05M
Market Cap:1.88B
PE:-13.13
High:27.02
Open:25.75
Low:25.17
Close:25.65
52wk High:31.34
52wk Low:16.00
Shares:70.96M
Float Shares:66.63M
Volume Ratio:1.41
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0200
EPS(LYR):-1.0800
ROE:-72.31%
ROA:-24.14%
PB:23.42
PE(LYR):-24.56

Loading ...

Zymeworks is Maintained at Buy by Truist Securities

Dow Jones
·
13 hours ago

Zymeworks Inc. : Truist Securities Raises Target Price to $34 from $32

THOMSON REUTERS
·
Yesterday

Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul

Reuters
·
Oct 02

Vir Biotechnology Names Aziz Sawaf as CFO Effective Oct. 5, 2026

Reuters
·
Oct 01

Zymeworks is Maintained at Buy by Citigroup

Dow Jones
·
Sep 30

Zymeworks Inc. : TD Cowen Reinstates Coverage with Buy Rating; Price Target $34

THOMSON REUTERS
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Zymeworks price target raised to $39 from $38 at Citi

TIPRANKS
·
Sep 29

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

MT Newswires Live
·
Sep 28

GUIDANCE: (ZYME) Zymeworks Expects 2026 Revenue Range $278M - $292M

MT Newswires Live
·
Sep 28

Zymeworks announces financial impact of Theravance Biopharma acquisition

TIPRANKS
·
Sep 28

Zymeworks Inc. - Expects Total Revenue, Including Collaboration Revenue from Yupelri, for 2026 to be Between $278 Mln and $292 Mln

THOMSON REUTERS
·
Sep 28

Zymeworks Inc. Fy2026 REV View $311.7 Mln

THOMSON REUTERS
·
Sep 28

Zymeworks Outlook 2026 Adjusted Ebitda to be Between $114 Mln and $128 Mln

THOMSON REUTERS
·
Sep 28

Zymeworks Q2 FY26 Net Loss Widens to $45 Million; Revenue Guidance Rises to $278 Million-$292 Million for FY26

Reuters
·
Sep 28

Press Release: Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Dow Jones
·
Sep 28

Zymeworks Completes Acquisition of Theravance Biopharma

THOMSON REUTERS
·
Sep 24

Zymeworks Initiated at Outperform by Wolfe Research

Dow Jones
·
Sep 17

Zymeworks initiated with an Outperform at Wolfe Research

TIPRANKS
·
Sep 17

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

TIPRANKS
·
Sep 10